ABSTRACT
BACKGROUND: The natural history and its modulation by treatments administered for immune thrombocytopenia (ITP) in the clinical practice remains unknown. In addition, little information is available on the characteristics and management of ITP in Spain. METHODS: We conducted an observational, multicenter, registry in 70 Hematology Services from Spain between 2009 and 2011, which included children from 2 months of age and adults with primary ITP or another ITP diagnosed within the last 6 months (platelet count [PC] < 100 × 109/l). Patients were followed-up at 6 and 12 months. RESULTS: 484 patients were included (median [Q1, Q3] age 52 [29,74] years, 87.6% adults), 56% women, 10.5% with secondary ITP. Median (Q1, Q3) PC at diagnosis was 12 × 109/l (4, 32); 72% of patients had bleeding symptoms (62% cutaneous bleeding, 29% oral cavity bleeding, 18% epistaxis). 81% of patients with primary ITP received first-line treatment, mainly with corticosteroids (>6 weeks in 59% of cases), either alone (41%) or associated with intravenous immunoglobulin (33%). The response (≥30 × 109/L) to first-line treatment was 92%. A total of 19% of patients received second-line treatment and 6% additional treatments. At 12 months, 74% of primary ITP patients maintained a PC ≥ 100 × 109/L in absence of treatment (10% still had hemorrhagic manifestations). CONCLUSIONS: Characteristics of Spanish ITP patients are comparable to those from other countries. Although a high response rate to first-line treatments is observed, at 1 year, the disease persists in around one quarter of patients. Overall therapeutic management in Spain conforms to current recommendations, except for an excessive duration of corticosteroids therapy.
Subject(s)
Purpura, Thrombocytopenic, Idiopathic/diagnosis , Purpura, Thrombocytopenic, Idiopathic/therapy , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Algorithms , Biomarkers , Child , Child, Preschool , Comorbidity , Disease Management , Female , Hemorrhage/etiology , Humans , Immunoglobulins, Intravenous/therapeutic use , Infant , Male , Middle Aged , Phenotype , Platelet Count , Purpura, Thrombocytopenic, Idiopathic/epidemiology , Purpura, Thrombocytopenic, Idiopathic/etiology , Registries , Spain/epidemiology , Treatment Outcome , Young AdultSubject(s)
Anemia, Aplastic/etiology , Bone Marrow/pathology , Chromosomes, Human, Pair 8/genetics , Leukemia, Monocytic, Acute/genetics , Trisomy , Adult , Anemia, Aplastic/diagnosis , Anemia, Aplastic/genetics , Anemia, Aplastic/pathology , Clone Cells/ultrastructure , Fatal Outcome , Fever of Unknown Origin/etiology , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Leukemia, Monocytic, Acute/pathology , Male , Neoplastic Stem Cells/ultrastructure , Recurrence , Remission, SpontaneousABSTRACT
Desde hace algún tiempo se ha incrementado la aplicación de opciones terapéuticas no tradicionales, como el uso de las plantas a las que se les atribuyen propiedades medicinales. Entre las especies vegetales que han despertado interés por su acción in vitro contra algunos de los agentes que causan infecciones dermatológicas, está Gliricida sepium, que se conoce popularmente con el nombre de "mataratón". Para evaluar la actividad de G. sepium como tratamiento tópico en el manejo de infecciones cutáneas se diseñó un ensayo utilizando el extracto acuoso de la planta en mono de la familia Cebidae
